213 related articles for article (PubMed ID: 10384402)
21. Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia.
Zhou LX; Pihlstrom B; Hardwick JP; Park SS; Wrighton SA; Holtzman JL
Clin Pharmacol Ther; 1996 Aug; 60(2):191-8. PubMed ID: 8823237
[TBL] [Abstract][Full Text] [Related]
22. Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Bourgeois BF; Wad N
Ther Drug Monit; 1985; 7(4):405-10. PubMed ID: 4082240
[TBL] [Abstract][Full Text] [Related]
23. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
24. Determination of 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (Dihydrodiol) and quantitative studies of phenytoin metabolism in man.
Maguire JH; Kraus BL; Butler TC; Dudley KH
Ther Drug Monit; 1979; 1(3):359-70. PubMed ID: 555579
[TBL] [Abstract][Full Text] [Related]
25. Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man.
Witkin KM; Bius DL; Teague BL; Wiese LS; Boyles LW; Dudley KH
Ther Drug Monit; 1979; 1(1):11-34. PubMed ID: 553326
[TBL] [Abstract][Full Text] [Related]
26. Phenytoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin do not alter the effects of bacterial and amplified plaque extracts on cultures of fibroblasts from normal and overgrown gingivae.
Smith QT; Hinrichs JE
J Dent Res; 1987 Aug; 66(8):1393-8. PubMed ID: 3476609
[TBL] [Abstract][Full Text] [Related]
27. Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.
Aliwarga T; Cloyd JC; Goel V; Brundage RC; Marino SE; Leppik IE; Remmel RP
Ther Drug Monit; 2011 Feb; 33(1):56-63. PubMed ID: 21233690
[TBL] [Abstract][Full Text] [Related]
28. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
29. Phenytoin-induced gingival overgrowth.
Arya R; Gulati S
Acta Neurol Scand; 2012 Mar; 125(3):149-55. PubMed ID: 21651505
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics of phenytoin in gingival crevicular fluid and plasma in relation to gingival overgrowth.
McLaughlin WS; Ball DE; Seymour RA; Kamali F; White K
J Clin Periodontol; 1995 Dec; 22(12):942-5. PubMed ID: 8613563
[TBL] [Abstract][Full Text] [Related]
31. Hydroxylation of 5,5-diphenylhydantoin (phenytoin) by dog liver microsomes.
Butler TC; Dudley KH; Mitchell GN; Johnson D
Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):4-9. PubMed ID: 21639
[TBL] [Abstract][Full Text] [Related]
32. Folic acid and phenytoin induced gingival overgrowth--is there a preventive effect.
Prasad VN; Chawla HS; Goyal A; Gauba K; Singhi P
J Indian Soc Pedod Prev Dent; 2004 Jun; 22(2):82-91. PubMed ID: 15491092
[TBL] [Abstract][Full Text] [Related]
33. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
O'Leary TD; Sansom LN
J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
[TBL] [Abstract][Full Text] [Related]
34. Functional aesthetic treatment of patient with phenytoin-induced gingival overgrowth.
Luvizuto ER; da Silva JB; Campos N; Luvizuto GC; Poi WR; Panzarini SR
J Craniofac Surg; 2012 May; 23(3):e174-6. PubMed ID: 22627422
[TBL] [Abstract][Full Text] [Related]
35. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia.
Iacopino AM; Doxey D; Cutler CW; Nares S; Stoever K; Fojt J; Gonzales A; Dill RE
J Periodontol; 1997 Jan; 68(1):73-83. PubMed ID: 9029455
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
[TBL] [Abstract][Full Text] [Related]
37. Stereoselective inhibition of diphenylhydantoin metabolism by p-hydroxyphenyl-phenylhydantoin enantiomers in rats.
Huang JD; Hsieh CY
Chirality; 1991; 3(6):454-9. PubMed ID: 1812955
[TBL] [Abstract][Full Text] [Related]
38. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
39. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
Kim PM; Winn LM; Parman T; Wells PG
J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197
[TBL] [Abstract][Full Text] [Related]
40. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.
Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E
Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
